Gujarat Kidney & Super Speciality Ltd
Incorporated in 2019, Gujarat Kidney and Super Speciality Limited specializes in providing multispeciality healthcare services.[1]
- Market Cap ₹ 871 Cr.
- Current Price ₹ 110
- High / Low ₹ 123 / 98.2
- Stock P/E 92.6
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 51.5 %
- ROE 51.2 %
- Face Value ₹ 2.00
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
- Debtor days have improved from 229 to 138 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 0.00 | 4.77 | 40.24 | |
| 0.01 | 2.81 | 23.68 | |
| Operating Profit | -0.01 | 1.96 | 16.56 |
| OPM % | 41.09% | 41.15% | |
| 0.00 | 0.70 | 0.15 | |
| Interest | 0.00 | 0.07 | 0.65 |
| Depreciation | 0.00 | 0.32 | 3.29 |
| Profit before tax | -0.01 | 2.27 | 12.77 |
| Tax % | 0.00% | 24.67% | 25.53% |
| -0.01 | 1.71 | 9.50 | |
| EPS in Rs | -0.50 | 85.50 | 1.66 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 744% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 697% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 43% |
| Last Year: | 51% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 0.20 | 0.20 | 11.37 |
| Reserves | 0.17 | 10.60 | 14.57 |
| 0.00 | 5.86 | 8.31 | |
| 3.50 | 3.86 | 21.09 | |
| Total Liabilities | 3.87 | 20.52 | 55.34 |
| 0.00 | 13.64 | 31.01 | |
| CWIP | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 |
| 3.87 | 6.88 | 24.33 | |
| Total Assets | 3.87 | 20.52 | 55.34 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 0.00 | 1.21 | 13.61 | |
| 0.00 | 0.22 | -18.14 | |
| 0.00 | -0.47 | 6.16 | |
| Net Cash Flow | 0.00 | 0.97 | 1.63 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 321.38 | 137.51 | |
| Inventory Days | |||
| Days Payable | |||
| Cash Conversion Cycle | 321.38 | 137.51 | |
| Working Capital Days | 100.24 | -24.13 | |
| ROCE % | 19.26% | 51.52% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
11h - NCLT allowed voluntary revision of Board's Report and notes for FY2021-22 to FY2023-24; RoC filing and Rs.10,000 fee.
-
Statement Of Deviation And Variation For Quarter Ended 31 Decembre 2025
11h - No deviation in utilisation of Rs2,508,000,000 equity proceeds raised 24-12-2025.
-
Announcement under Regulation 30 (LODR)-Monitoring Agency Report
11h - Brickwork MA report (Dec 31, 2025): IPO proceeds Rs250.80cr; Rs50.04cr used; no deviations.
-
Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025
15h - Board approved unaudited standalone and consolidated Q3 and nine-month results to Dec 31, 2025; limited review unmodified.
-
Board Meeting Outcome for Outcome Of The Board Meeting Held On February 14 2026 For The Approval Of The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Nine Months Ended December 31 2025 And Other Businesses M
15h - Approved unaudited standalone and consolidated Q3 & 9M results to 31-Dec-2025; consolidated 9M income Rs5,159.43L, PAT Rs1,198.58L.
Annual reports
No data available.
Business Profile[1]
Gujarat Kidney and Super Speciality Limited is a regional healthcare operator in central Gujarat, running a chain of mid-sized multi-speciality hospitals focused on secondary and tertiary care.